Company patents
TOOLGEN INCORPORATED
TOOLGEN INCORPORATED's patent strategy shows a surprising decline in its core pharma_biotech categories, with Pharmaceutical Preparations dropping by 33.3% in 2025 and 100.0% so far in 2026, and Therapeutic Activity (Pharma) completely ceasing new filings in 2025 and 2026, despite these areas collectively representing over 50% of its portfolio. This suggests a significant shift away from these previously dominant areas, with a minor, albeit inconsistent, emerging interest in Animal Husbandry / Fishing, which saw one patent so far in 2026.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
57 US filings (since 2023) · 5 categories · 7 themes
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Assays leveraging CRISPR-Cas systems (e.g., Cas12, Cas13) for highly specific and sensitive detection of target nucleic acids, often involving collateral cleavage activity or reporter molecules.
Therapeutic approaches involving the use of living cells, often genetically modified or ex vivo activated, to treat diseases, particularly cancer, by modulating immune responses or replacing damaged cells.
Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.
Development and use of animal subjects, often genetically modified, to study human diseases, test treatments, or understand biological processes.
Development and application of therapeutic proteins or peptides produced through recombinant DNA technology, including fusion proteins and modified growth factors.
Patents
Showing 1-6 of 6
Cellular Immunotherapy